Opus Genetics Stock Today
| IRD Stock | 1.93 0.07 3.50% |
PerformanceWeakest
| Odds Of DistressRisky
|
Opus Genetics is trading at 1.93 as of the 11th of January 2026, a 3.5% down since the beginning of the trading day. The stock's lowest day price was 1.89. Opus Genetics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 12th of December 2025 and ending today, the 11th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of May 2005 | Category Healthcare | Classification Health Care |
Opus Genetics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 68.96 M outstanding shares of which 635.92 K shares are currently shorted by investors with about 1.09 days to cover. More on Opus Genetics
Moving against Opus Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Opus Stock Highlights
| CEO Director | MBA MD | ||||
| Old Name | Groupe IRD | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsOpus Genetics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Opus Genetics' financial leverage. It provides some insight into what part of Opus Genetics' total assets is financed by creditors.
| |||||
Opus Genetics (IRD) is traded on NASDAQ Exchange in USA and employs 18 people. Opus Genetics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 133.1 M. Opus Genetics runs under Pharmaceuticals sector within Health Care industry. The entity has 68.96 M outstanding shares of which 635.92 K shares are currently shorted by investors with about 1.09 days to cover.
Opus Genetics generates negative cash flow from operations
Check Opus Genetics Probability Of Bankruptcy
Ownership AllocationOpus Genetics owns a total of 68.96 Million outstanding shares. Opus Genetics holds significant amount of outstanding shares owned by insiders and institutional investors . Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Opus Ownership Details
Opus Genetics Historical Income Statement
Opus Stock Against Markets
Opus Genetics Corporate Management
| Joseph MBA | Chief Officer | Profile | |
| Jenny Kobin | Investor Officer | Profile | |
| Robert Gagnon | Chief Officer | Profile | |
| Bernhard MBA | Senior Secretary | Profile | |
| Ashwath Jayagopal | Chief Officer | Profile | |
| Bindu Manne | Head Commercialization | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Opus Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.86) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
The market value of Opus Genetics is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics' value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics' market value can be influenced by many factors that don't directly affect Opus Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.